vimarsana.com
Home
Live Updates
Blood Test for MS Activity Gets FDA Breakthrough Designation
Blood Test for MS Activity Gets FDA Breakthrough Designation
Blood Test for MS Activity Gets FDA Breakthrough Designation
Roche's Elecsys NfL test is intended to be used as an aid in detection of disease activity in adults with relapsing-remitting multiple sclerosis or secondary progressive multiple sclerosis.
Related Keywords
Matt Sause ,
Drug Administration ,
Elecsys Neurofilament Light Chain ,
Medscape Medical News ,
Elecsys Nfl ,
Multiple Sclerosis Ms ,
Multiple Sclerosis ,
Us ,
Multiple Sclerosis Progression ,
Als Progression ,
Multiple Sclerosis Prognosis ,
S Prognosis ,
Ultiple Sclerosis Prognostic Factors ,
S Prognostic Factors ,
Secondary Progressive Multiple Sclerosis ,
Pms ,
Blood ,
Relapsing Remitting Multiple Sclerosis ,
Arms ,
Ultiple Sclerosis Relapsing Remitting ,
Disability ,
Us Food And Drug Administration ,
United State ,